



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat

Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058

CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2014

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Jun-14 (Unaudited)	Quarter Ended 30-Jun-13 (Unaudited)	Quarter Ended 31-Mar-14 (Audited)	Year Ended 31-Mar-14 (Audited)
1 (a). Net Income from Sales / Services	1,413.84	1,843.35	1,216.04	6,484.06
(b). Other Operating Income	3.83	36.75	4.88	58.62
Total Income	1,417.67	1,880.10	1,220.92	6,542.68
2. Expenditure				
a) (Increase)/Decrease in Stock in Trade/WIP	114.26	171.20	(158.17)	280.00
b) Consumption of Raw Materials	1,177.47	1,633.03	1,147.48	5,697.70
c) Purchase of Traded Goods	0.00	0.00	0.00	0.00
d) Employee Costs	18.79	12.76	25.56	68.41
e) Depreciation	8.65	8.08	8.30	33.09
f) Other Expenditure				
(i) Manufacturing Expenses	24.76	38.01	128.08	230.08
(ii) Administration Expenses	11.40	16.37	9.89	57.67
(iii) Selling & Distribution Expenses	12.69	14.97	17.01	80.92
g) Total	1,368.02	1,894.42	1,178.15	6,447.87
3. Profit from Operations before Other Income, Interest and Exceptional Items	49.65	(14.32)	42.77	94.81
4. Other Income	3.00	1.80	6.50	21.26
5. Profit before Interest and Exceptional items	52.65	(12.52)	49.27	116.07
6. Interest	12.24	20.55	9.33	75.34
7. Profit after Interest but before Exceptional items	40.41	(33.07)	39.94	40.73
8. Exceptional Items	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax	40.41	(33.07)	39.94	40.73
10. Tax expense (incl deferred tax)	16.48	1.13	5.06	16.56
11. Net Profit / (Loss) from ordinary activities after tax	23.93	(34.20)	34.88	24.17
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	23.93	(34.20)	34.88	24.17
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	1,028.80	946.51	1,004.91	1,004.91
16. Earnings per share				
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.77	(1.11)	1.13	0.78
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.77	(1.11)	1.13	0.78
17. Public shareholding				
-- Number of shares	1,644,269	1,644,269	1,644,269	1,644,269
-- Percentage of shareholding	53.22	53.22	53.22	53.22
18. Promoters and promoter group shareholding**				
a) Pledged/ Encumbered				
-- Number of shares	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00

b) Non-encumbered				
-- Number of shares	1,445,431	1,445,431	1,445,431	1,445,431
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	46.78	46.78	46.78	46.78

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2014
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Thursday, 14 August 2014 at the Corporate Office of the Company.
4. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 30 June, 2014

Opening Balance as on	1/Apr/2014	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	30/Jun/2014	0

**By order of the Board of Directors
For Samrat Pharmachem Limited**

**Place : Mumbai
Date : 14 August 2014**

**Rajesh Mehta
Executive Director**